It is now clear that the most appropriate management of bronchial asthma is to control airway inflammation. 1," The drugs able to reduce inflammation in asthmatic children are in the following order of decreasing activity: systemic steroids; inhaled steroids (IS); nedrocromil sodium (NED); sodium cromoglycate (SGC); and probably ketotifen. -s The anti-inflammatory role of the new long-acting beta-2 agonist, salmeterol, has not been established because a 12-week treatment period of doses effective in controlling symptoms did not show any significant effect on mast cells, eosinophils, T-cells or the epithelium of bronchial mucosa and submucosa. 6 Anti-inflammatory drugs and mild-tomoderate asthma
The international guidelines about asthma management suggest regular anti-inflammatory therapy should be given in mild persistent, moderate and severe asthma. Only mild episodic asthma should be treated exclusively with environmental control and beta-2 agonist on demand. However, it is not certain which anti-inflammatory agent should be used as first-line therapy. [7] [8] [9] Corticosteroids are the most effective anti-inflammatory drugs, but they have a number of side effects (Tables 1 and 2 (Fig. 7) . Two months after NED (16 mg/day), the findings were unchanged (Fig. 8) . Fourteen days on Deflazacort (2 mg/Kg/day) brought about a reduction in bronchial inflammation (Fig. 9 ). 
